CRISPR/Cas9-mediated knockout of NEAT1 attenuates neurotoxicity in 6-hydroxydopamine model of Parkinson’s disease
Iranian Journal of Basic Medical Sciences · 2026-06 · 29 (6) · 915-926
DOI: 10.22038/ijbms.2026.93063.20075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Basic Medical Sciences, 2026-06. Verfasst von Ali Samareh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective(s): Parkinson’s disease (PD), a progressive neurodegenerative condition, involves the degeneration of dopaminergic neurons and the aggregation of α-synuclein (SNCA); however, the molecular mechanisms of this disorder remain incompletely understood.Materials and Methods: This study explores the role of the long non-coding RNA NEAT1 in PD by employing CRISPR/Cas9-mediated knockout in SH-SY5Y neuroblastoma cells treated with 6-hydroxydopamine (6-OHDA).
Results
Deletion of NEAT1 was associated with increased cellular viability, attenuated both cytotoxicity and apoptosis, and elevated total antioxidant capacity (TAC), alongside a marked down-regulation of SNCA expression. Mechanistically, NEAT1 knockout was accompanied by increased hsa-let-7a-5p and decreased miR-506-3p expression, suggesting its function as a competing endogenous RNA (ceRNA) in miRNA-mediated stress pathways. Tyrosine hydroxylase (TH) levels remained unchanged, indicating that NEAT1 may influence neurotoxicity through post-transcriptional mechanisms.
Conclusion
These results suggest NEAT1 is a crucial modulator of neurotoxicity in PD, with its inhibition offering therapeutic promise. Despite the in vitro nature of this study, our findings provide foundational insight into NEAT1’s dualistic roles in neurodegeneration and underscore its potential as a therapeutic target in PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Clinical Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
- Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Zitieren
APA
Samareh, A., Nematollahi, M. H., Pourghadamyari, H., Rastegar, S., Ebrahimi, H., Hadizadeh, M., Wang, H., Tao, L., Sasan, H., & Asadikaram, G. (2026). CRISPR/Cas9-mediated knockout of NEAT1 attenuates neurotoxicity in 6-hydroxydopamine model of Parkinson’s disease. Iranian Journal of Basic Medical Sciences, 29(6), 915-926. https://doi.org/10.22038/ijbms.2026.93063.20075
Vancouver
Samareh A, Nematollahi MH, Pourghadamyari H, Rastegar S, Ebrahimi H, Hadizadeh M, et al. CRISPR/Cas9-mediated knockout of NEAT1 attenuates neurotoxicity in 6-hydroxydopamine model of Parkinson’s disease. Iranian Journal of Basic Medical Sciences. 2026;29(6):915-926. doi:10.22038/ijbms.2026.93063.20075
BibTeX
@article{Samareh2026,
author = {Samareh, Ali and Nematollahi, Mohammad Hadi and Pourghadamyari, Hossein and Rastegar, Sanaz and Ebrahimi, Hosseinali and Hadizadeh, Morteza and Wang, Hongsheng and Tao, Lijun and Sasan, Hosseinali and Asadikaram, Gholamreza},
title = {CRISPR/Cas9-mediated knockout of NEAT1 attenuates neurotoxicity in 6-hydroxydopamine model of Parkinson’s disease},
journal = {Iranian Journal of Basic Medical Sciences},
year = {2026},
volume = {29},
number = {6},
pages = {915--926},
doi = {10.22038/ijbms.2026.93063.20075}
}
EUVIMED